Overview of current pharmacotherapy for infantile hemangiomas

Abstract

Abstract: Infantile hemangiomas (IH) are the most common tumors of infancy and childhood. 60% of them are localized in the head and neck region. They may impinge on vital structures, ulcerate, bleed, cause high-output cardiac failure or significant disfigurement if left untreated. The traditional treatment methods include drug therapy, laser therapy and surgery, with drug therapy being the mainstay of treatment. The medications most commonly used to treat IH are corticosteroids, beta-adrenergic blocker, pingyangmycin, interferon alfa, imiquimod, and etc. For function- and life-threatening infantile hemangioma, some anti-cancer agents like vincristine may be used as an effective alternative option. This succinct review summarized current pharmacotherapeutic therpy of IH, especially the properties and effectiveness of various beta-adrenergic antagonists in the management of IH.

Key words: Infantile hemangioma, Drug therapy, beta-adrenergic blocker

ZHENG Jia-wei, MA Kun-ning, ZHANG Ling. Overview of current pharmacotherapy for infantile hemangiomas[J]. China Journal of Oral and Maxillofacial Surgery, 2014, 12(1): 1-6.

References

[1] Shah S, Frieden IJ. Treatment of infantile hemangiomas with Beta-blockers: a review[J]. Skin Therapy Lett, 2013,18(6):5-7.
[2] 郑家伟.婴幼儿血管瘤“等待观察”的治疗策略应予改变[J].中国口腔颌面外科杂志,2012,10(2):163-164.
[3] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008,358(24):2649-2651.
[4] Zimmermann AP, Wiegand S, Werner JA, et al. Propranolol therapy for infantile haemangiomas: review of the literature[J]. Int J Pediatr Otorhinolaryngol, 2010,74(4):338-342.
[5] Raphaël MF, de Graaf M, Breugem CC, et al. Atenolol: a promising alternative to propranolol for the treatment of hemangiomas[J]. J Am Acad Dermatol, 2011,65(2):420-421.
[6] Vedin A, Wilhelmsson C, BjÖrntorp P. Induction of diabetes and oral glucose tolerance tests during and after chronic beta-blockade[J]. Acta Med Scand Suppl, 1975,575:37-40.
[7] Eichhorn EJ. Effects of bucindolol in heart failure[J]. Am J Cardiol, 1993,71(9):65C-70C.
[8] Takase B, Hikita H, Uehata A, et al. Effect of carteolol on silent myocardial ischemia, variability in heart rate, and the pain-modulating system[J]. Am Heart J, 1997,134(5 Pt 1):945-954.
[9] Production Information: COREg (R) oral tablets, carvedilol oral tablets[Z]. GlaxosmithKline, Research Triangle Park, NC, 2011.
[10] Brogden RN, Heel RC, Speight TM, et al. Labetalol: a review of its pharmacology and therapeutic use in hypertension[J]. Drugs, 1978,15(4):251-270.
[11] Pope E, Chakkittakandiyil A, Lara-Corrales I, et al.Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol[J]. Br J Dermatol, 2013,168(1):222-224.
[12] McDevitt DG. Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs[J]. Eur Heart J,1987, Suppl M:9-14.
[13] Production information: levatol (R) oral tablet, penbutolol sulfate oral tablets[Z]. Schwarz Pharma, LLC(per FDA), Smyrna, GA, 2010.
[14] Isaac MT. Review: combining pindolol with an SSRI improves early outcomes in people with depression[J]. Evid Based Ment Health, 2004,7(4):107.
[15] Lynch M, Lenane P, O'Donnell BF. Propranolol for the treatment of infantile haemangiomas: our experience with 44 patients[J]. Clin Exp Dermatol, 2013,Dec 2.
[16] Saul JP, Schaffer MS, Karpawich PP, et al. Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia[J]. J Clin Pharmacol, 2001,41(1):35-43.
[17] Oranje AP, Janmohamed SR, Madern GC, et al.Treatment of small superficial haemangioma with timolol 0.5% ophthalmic solution:a series of 20 cases[J].Dermatology,2011,223(4):330-334.
[18] Fuchsmann C, Quintal MC, Giguere C, et al. Propranolol as first-line treatment of head and neck hemangiomas[J]. Arch Otolaryngol Head Neck Surg, 2011,137(5):471-478.
[19] de Graaf M, Raphael MF, Breugem CC, et al.Treatment of infantile haemangiomas with atenolol: Comparison with a historical propranolol group[J]. J Plast Reconstr Aesthet Surg, 2013,66(12):
[20] Production information: KERLONE (R) oral tablets, betaxolol hydrochloride oral tablets[Z]. Sanofi Synthelabo Inc., New York, NY, 2003.
[21] Production information: bisoprolol fumarate oral tablet[Z]. Teva Pharmaceuticals, Sellersvills, PA, 2003
[22] Production information: esmolol hydrochloride IV injection, esmolol hydrochloride IV injection[Z]. APP Pharmaceuticals, LLC, Schaumburg, IL, 2008.
[23] Greenberger S, Boscolo E, Adini I, et al. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells[J]. N Engl J Med, 2010,362(11):1005-1013.
[24] Zhou Q, Yang XJ, Zheng JW, et al. Short-term high-dose oral prednisone on alternate days is safe and effective for treatment of infantile hemangiomas[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010,109(2):166-167.
[25] Tan BH, Leadbitter PH, Aburn NH, et al. Steroid therapy for problematic proliferating haemangioma[J]. N Z Med J, 2011,124(1329):57-65.
[26] Izadpanah A, Izadpanah A, Kanevsky J, et al. Propranolol versus prednisone in the treatment of infantile hemangiomas: a retrospective comparative study[J]. Plast Reconstr Surg, 2013,131(3):601-613.
[27] Price CJ, Lattouf C, Baum B, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis[J]. Arch Dermatol, 2011,147(12):1371-1376.
[28] Martinez MI, Sanchez-Carpintero I, North PE, et al. Infantile hemangioma: clinical resolution with 5% imiquimod cream[J]. Arch Dermatol, 2002,138(7):881-884.
[29] Qiu Y, Ma G, Yang J, et al. Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study[J]. Clin Exp Dermatol, 2013,38(8):845-850.
[30] Chang E, Boyd A, Nelson CC, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b[J]. J Pediatr Hematol Oncol, 1997,19(3):237-244.
[31] Gottschling S, Schneider G, Meyer S, Reinhard H, et al. Two infants with life-threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide[J].Pediatr Blood Cancer,2006,46(2):239-242.
[32] Fahrtash F, McCahon E, Arbuckle S. Successful treatment of kaposiform hemangioendothelioma and tufted angioma with vincristine[J]. J Pediatr Hematol Oncol, 2010,32(6):506-510.
[33] Fernandez-Pineda I, Lopez-Gutierrez JC, Chocarro G, et al. Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon[J]. Pediatr Blood Cancer, 2013,60(9):1478-1481.
[34] Fuchimoto Y, Morikawa N, Kuroda T, et al. Vincristine, actinomycin D, cyclophosphamide chemotherapy resolves Kasabach-Merritt syndrome resistant to conventional therapies[J]. Pediatr Int, 2012,54(2):285-287.
[35] Hou J, Wang M, Tang H, et al. Pingyangmycin sclerotherapy for infantile hemangiomas in oral and maxillofacial regions: an evaluation of 66 consecutive patients[J]. Int J Oral Maxillofac Surg, 2011,40(11):1246-1251.
[36] 郑家伟,赵怡芳.平阳霉素治疗脉管性疾病规范[J]. 中国口腔颌面外科杂志,2011,9(1):68-69.